Vir Biotechnology director Saira Ramasastry resigns; board shrinks to 7; annual meeting elects directors

On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.

Proposal 1. Election of Directors The Company’s stockholders elected the three persons listed below as Class I directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Robert More, MBA 114,856,835 6,833,096 16,677,343 Janet Napolitano, J.D. 67,235,175 54,454,756 16,677,343 Elliott Sigal, M.D., Ph.D. 115,030,681 6,659,250 16,677,343

Proposal 3. Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 137,048,756 153,836 1,164,682 0

Proposal 2. Advisory Vote on Executive Compensation The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 108,453,963 11,863,405 1,372,563 16,677,343